Am J Transplant, Volume 18, Suppl 3 Archives - ATC Abstracts

2018 American Transplant Congress
Living Liver Donors Face Substantial Out-of-Pocket Donation-Related Costs
J. Ruck, A. Massie, J. Garonzik-Wang, S. Ottman, A. Cameron, B. Philosophe, D. Segev.
Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD.
While financial barriers to living kidney donation have been recognized, and the associated costs have been characterized limited data exist on the costs incurred by…
2018 American Transplant Congress
Hepatitis C Recurrence after Liver Transplant: A Comparison of Antibody Induction versus No Antibody Induction
S. Patel, J. Jin, E. Benedetti, P. West-Thielke.
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Hepatitis C virus (HCV) recurrence after orthotopic liver transplant (OLT) is universal and exhibits accelerated progression to cirrhosis. Progression can be mitigated by new…
2018 American Transplant Congress
The Technique of Ileobladder and Kidney Transplantation in Rats and Pigs
M. Haberal,¹ M. Kirnap,¹ D. Ersoz,¹ D. Bacanli,² Z. Ersoy,³ M. Bayzakov,¹ A. Torgay,³ H. Ozdemir.⁴
¹Transplantation, Baskent University, Ankara, Turkey; ²Research Center, Baskent University, Ankara, Turkey; ³Anesthesiology, Baskent University, Ankara, Turkey; ⁴Pathology, Baskent University, Ankara, Turkey.
Introduction: Small, poor compliant or unstable bladders are a major problem in patients waiting for renal transplantation (RT). The experimental technique aims to develop and…
2018 American Transplant Congress
Maximizing Utilization in Pancreas Transplantation: Phenotypic CharacteristicsDifferentiating Aggressive from Nonaggressive Transplant Centers
O. K. Serrano,¹ D. M. Vock,² T. B. Dunn,¹ R. Kandaswamy,¹ E. B. Finger.¹
¹Surgery, University of Minnesota, Minneapolis, MN; ²Biostatistics, University of Minnesota, Minneapolis, MN.
OBJECTIVE: Given the increasing shortage of deceased donor pancreas allografts and their declining acceptance rate, maximizing utilization requires a balance between donor selection and transplant…
2018 American Transplant Congress
Phosphoproteomic Analysis of Mouse Hepatic Ischemia/Reperfusion Injury
A. Zarrinpar,² S. Duarte,¹ Y. Lai.²
¹Surgery, University of California, Los Angeles, CA; ²Surgery, University of Florida, Gainesville, FL.
Introduction: Hepatic ischemia/reperfusion injury (IRI) is a major risk factor for acute rejection and early graft dysfunction in liver transplantation. The large and complex landscape…
2018 American Transplant Congress
Early versus Late Cytomegalovirus Prophylaxis after Kidney Transplant
M. Harris, J. Byrns, J. Gommer, M. Laub, M. Ellis.
Duke University Hospital, Durham, NC.
Background: Prophylaxis against cytomegalovirus (CMV) is recommended in high-risk patients (CMV D+/R-) and those who are CMVR+ and getting T-cell depletional therapy. It is unclear…
2018 American Transplant Congress
Early Blockade of Toll-Like Receptor 4 Reduces Ischemia-Reperfusion Injury and Improves Islet Transplantation Outcomes
C. Chang,¹ M. Lawrence,² R. Kane,¹ B. Naziruddin.³
¹Institute of Biomedical Studies, Baylor University, Waco; ²Baylor Scott & White Research Institute, Dallas; ³Baylor Simmons Transplant Institute, Dallas.
Purpose: Inflammatory damage to islets during isolation is a major hurdle for success in transplantation. We investigated the safety and therapeutic potential of pharmacological blockade…
2018 American Transplant Congress
Is KDPI Valid for Hepatitis C Aviremic Kidneys?
L. Sibulesky,¹ C. Kling,¹ C. Blosser,² C. Johnson,² A. Limaye,² R. Bakthavatsalam,¹ N. Leca,² J. Perkins.¹
¹Surgery, University of Washington Medical Center, Seattle, WA; ²Medicine, University of Washington Medical Center, Seattle, WA.
KDRI is an estimate of post-transplant kidney graft failure. It is based on ten donor factors that independently affect transplant outcomes, including HCV status from…
2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
J. Lee,¹ J. Park,² Y. Jung,¹ D. Kim,¹ J. Lee,¹ S. Song,³ J. Lee,⁴ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Internal Medicine (Gastroenterology), Yonsei University College of Medicine, Seoul, Korea; ³Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ⁴Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁵Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…
2018 American Transplant Congress
mTOR Inhibition with Everolimus in De Novo Living Donor Liver Transplantation – 24-Months Results from the H2307 Pivotal Trial
L. Jeng,¹ S. Lee,¹ A. Soin,¹ S. Uemoto,¹ D. Maluf,¹ J. Emond,¹ M. Meier,² J. Kochuparampil,² C. Sips,² S. Kaneko,³ G. Levy.¹
¹H2307 Study Group, Taichung, Taiwan; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Pharma KK, Tokyo, Japan.
Purpose: Everolimus (EVR) with reduced-dose tacrolimus (rTAC) has been shown to be efficacious in preventing graft rejection and improving renal function in deceased-donor liver transplant…

1
2
3
…
211
Next Page »